80
Participants
Start Date
August 1, 2024
Primary Completion Date
July 31, 2026
Study Completion Date
July 31, 2026
Usual Care group
Participants will use the same CGM and Insulclock® devices, but in blinded mode (no data available to the patient). Insulin therapy will be adjusted using capillary blood glucose measurements (4 times daily). Device data will be collected retrospectively but not used for treatment decisions.
Technological group
Participants will use a real-time continuous glucose monitoring device (e.g., FreeStyle Libre 2) and the Insulclock® smart insulin pen cap. Both devices provide real-time feedback and data on insulin administration and glucose levels. Patients will adjust their insulin therapy based on these data.
RECRUITING
Hospital La Fe, Valencia, Valencia
Instituto de Investigacion Sanitaria La Fe
OTHER